Quantcast

Leading Neurosurgical Center in Moscow Purchases CyberKnife System to Expand Ability to Treat Brain and Spinal Tumors

August 7, 2008

SUNNYVALE, Calif., Aug. 7 /PRNewswire-FirstCall/ — Accuray Incorporated , a global leader in the field of radiosurgery, announced today that the Burdenko Institute of Neurosurgery in Moscow has purchased a CyberKnife(R) Robotic Radiosurgery System. When the system is installed, the Burdenko Institute will become the second facility in Russia to offer advanced robotic radiosurgery treatments.

The CyberKnife System will enable the Burdenko Institute to expand its ability to treat tumors and other diseases of the brain and spine. With real-time image guidance and the ability to adjust for patient and tumor movement during treatment, clinicians are able to deliver radiation with extreme precision without requiring patients to be positioned in uncomfortable frames. Because it is non-invasive and does not require the use of frames, the CyberKnife System is ideal for those users who wish to deliver fractionated intracranial treatments.

“The Burdenko Institute is world renowned for its expertise in the treatment of neurological conditions,” said Eric P. Lindquist, senior vice president and chief marketing officer of Accuray Incorporated. “With the addition of a CyberKnife System, clinicians there will be able to expand their radiosurgical capabilities, while offering patients a viable, non-invasive alternative to traditional surgery.”

Established in 1932 as the Moscow Institute of Neurosurgery the facility focused specifically on neurosurgery. The institute was later renamed for Nikolai Nilovich Burdenko, who is regarded as the founder of Russian neurosurgery. The Burdenko Institute currently is led by Alexander N. Konovalov, M.D., Ph.D., who has served as its director for more than 32 years and is one of the foremost figures in Russian neurosurgery.

The Burdenko Institute will receive its CyberKnife System by the end of the 2008 calendar year through local distributor Newstep Ltd.

About the CyberKnife(R) Robotic Radiosurgery System

The CyberKnife Robotic Radiosurgery System is the world’s only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.

About Accuray

Accuray Incorporated , based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit http://www.accuray.com/.

Safe Harbor Statement

The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release relating to clinical studies, regulatory review and approval, and commercialization of products are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: market acceptance of products; competing products, the combination of our products with complementary technology; and other risks detailed from time to time under the heading “Risk Factors” in our report on Form 10-K for the year ended June 30, 2007 as updated from time to time by our quarterly reports on Form 10-Q and our other filings with the Securities and Exchange Commission. The Company’s actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.

Accuray Incorporated

CONTACT: Susan Lehman of Rockpoint Public Relations, +1-510-832-6006,susan@rockpointpr.com, for Accuray; or Stephanie Tomei, Public RelationsManager of Accuray Incorporated, +1-408-789-4234, stomei@accuray.com

Web site: http://www.accuray.com/




comments powered by Disqus